Overview of Therapeutic Inertia in Diabetes: Prevalence, Causes, and Consequences | Zendy

Susan Karam | Zendy; Jared Dendy | Zendy; Shruti Polu | Zendy; Lawrence Blonde | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Overview of Therapeutic Inertia in Diabetes: Prevalence, Causes, and Consequences

Author(s) -

Susan Karam,

Jared Dendy,

Shruti Polu,

Lawrence Blonde

Publication year - 2020

Publication title -

diabetes spectrum

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.716

H-Index - 31

eISSN - 1944-7353

pISSN - 1040-9165

DOI - 10.2337/ds19-0029

Subject(s) - medicine , diabetes mellitus , intensive care medicine , therapeutic effect , inertia , pharmacology , endocrinology , physics , classical mechanics

Many people with diabetes do not achieve individualized treatment targets. Therapeutic inertia, the underuse of effective therapies in preventing serious clinical end points, is a frequent, important contributor to this failure. Clinicians, patients, health systems, payors, and producers of medications, devices, and other products for those with diabetes all play a role in the development of therapeutic inertia and can all help to reduce it.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research